


WHAT IS CLAIMED IS:

1. A mutual salt of raloxifene and bisphosphonic acid of formula (I):

5



wherein:

- R<sub>1</sub> is C<sub>1-6</sub> alkyl optionally substituted with one or more substituents selected from the group consisting of NR<sub>3</sub>R<sub>4</sub>, OH, halogen, C<sub>1-6</sub> alkylthio, phenyl, C<sub>3-7</sub> cycloalkyl optionally substituted with NR<sub>3</sub>R<sub>4</sub> or OH, imidazolyl, pyridyl and imidazopyridyl; C<sub>3-6</sub> cycloalkyl optionally substituted with one or more substituents selected from the group consisting of NR<sub>3</sub>R<sub>4</sub>, OH, halogen, C<sub>1-6</sub> alkylthio, phenyl, morpholine and pyridyl; NR<sub>3</sub>R<sub>4</sub>; halogen; C<sub>1-6</sub> alkylthio optionally substituted with one or more substituents selected from the group consisting of NR<sub>3</sub>R<sub>4</sub>, OH, halogen and phenyl; or phénylthio optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, trifluoromethyl, CONR<sub>3</sub>R<sub>4</sub> and CO<sub>2</sub>H;
- 10 R<sub>2</sub> is hydrogen, OH or halogen;
- 15 R<sub>3</sub> and R<sub>4</sub> are each independently hydrogen, C<sub>1-6</sub> alkyl or C<sub>3-6</sub> cycloalkyl, wherein R<sub>3</sub> and R<sub>4</sub> are optionally fused together with the nitrogen atom to which they are attached to form a 5

20 to 7-membered ring;

x is 0.5 or 1; and

y is an integer in the range of 0 to 10.



2. The mutual salt of claim 1, wherein R<sub>1</sub> is C<sub>1-6</sub> alkyl optionally substituted with one or  
25 more substituents selected from the group consisting of NR<sub>3</sub>R<sub>4</sub>, imidazolyl and pyridyl;

NR<sub>3</sub>R<sub>4</sub>; halogen; or phenylthio substituted with halogen, and y is an integer of 0 to 7.

3. The mutual salt of claim 1, wherein the bisphosphonic acid part is selected from the group consisting of 1-hydroxyethylidene bisphosphonic acid (etidronic acid),  
5 dichloromethylidene bisphosphonic acid (clodronic acid), 3-amino-1-hydroxypropylidene bisphosphonic acid (pamidronic acid), 4-amino-1-hydroxybutylidene bisphosphonic acid (alendronic acid), 4-chlorophenylthiomethylidene bisphosphonic acid (tiludronic acid), 3-(N-methyl-N-n-pentyl)amino-1-hydroxypropylidene bisphosphonic acid (ibandronic acid), 1-hydroxy-2-(3-pyridinyl)ethylidene bisphosphonic acid (risedronic acid),  
10 cycloheptylaminomethylidene bisphosphonic acid (incadronic acid), 1-hydroxy-2-(1-imidazolyl)ethylidene bisphosphonic acid (zoledronic acid) and 1-hydroxy-3-(pyrrolidinyl)propylidene bisphosphonic acid.
4. The mutual salt of claim 1, which is raloxifene 1/2etidronate 5/2hydrate, raloxifene pamidronate trihydrate, raloxifene alendronate pentahydrate, raloxifene risedronate trihydrate, raloxifene incadronate monohydrate, or raloxifene zoledronate tetrahydrate.  
15
5. The mutual salt of claim 1, which is raloxifene alendronate pentahydrate.
- 20 6. The mutual salt of claim 5, whose powder X-ray diffraction spectrum ( $I/I_0 \geq 20$ ) shows at  $2\theta$  values of  $4.2 \pm 0.2$ ,  $8.4 \pm 0.2$ ,  $9.4 \pm 0.2$ ,  $9.7 \pm 0.2$ ,  $10.8 \pm 0.2$ ,  $13.3 \pm 0.2$ ,  $13.8 \pm 0.2$ ,  $14.2 \pm 0.2$ ,  $16.7 \pm 0.2$ ,  $18.3 \pm 0.2$ ,  $18.6 \pm 0.2$ ,  $19.4 \pm 0.2$ ,  $19.8 \pm 0.2$ ,  $20.5 \pm 0.2$ ,  $20.8 \pm 0.2$ ,  $21.2 \pm 0.2$ ,  $21.6 \pm 0.2$ ,  $25.5 \pm 0.2$  and  $26.9 \pm 0.2$ .
- 25 7. The mutual salt of claim 1, which is raloxifene risedronate trihydrate.
8. The mutual salt of claim 7, whose powder X-ray diffraction spectrum ( $I/I_0 \geq 20$ ) shows at  $2\theta$  values of  $6.8 \pm 0.2$ ,  $10.3 \pm 0.2$ ,  $12.3 \pm 0.2$ ,  $15.2 \pm 0.2$ ,  $16.5 \pm 0.2$ ,  $17.0 \pm 0.2$ ,  $17.3 \pm 0.2$ ,

$17.7 \pm 0.2$ ,  $20.3 \pm 0.2$ ,  $20.9 \pm 0.2$ ,  $21.2 \pm 0.2$ ,  $19.4 \pm 0.2$ ,  $19.8 \pm 0.2$ ,  $20.5 \pm 0.2$ ,  $20.8 \pm 0.2$ ,  $21.2 \pm 0.2$ ,  
 $21.6 \pm 0.2$ ,  $25.5 \pm 0.2$  and  $26.9 \pm 0.2$ .

9. A process for preparing a mutual salt of raloxifene and bisphosphonic acid of formula (I),  
 5 which comprises the step of reacting a compound of formula (II) or its solvate with a compound of formula (III) or its solvate, in a solvent:




- 10 wherein  $R_1$  and  $R_2$  have the same meanings as defined in claim 1.

10. The process of claim 9, wherein the solvent is selected from the group consisting of water, methanol, ethanol, propanol, isopropanol, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and a mixture thereof.

15


11. A pharmaceutical composition for preventing and treating osteoporosis comprising the mutual salt of formula (I) as an active ingredient together with pharmaceutically acceptable carriers:

20



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, x and y have the same meanings as defined in claim 1.


- 5 12. A pharmaceutical composition for preventing and treating hypercalcemia comprising  
the mutual salt of formula (I) as an active ingredient together with pharmaceutically  
acceptable carriers:



10

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, x and y have the same meanings as defined in claim 1.

13. A pharmaceutical composition for preventing and treating hyperlipidemia comprising  
the mutual salt of formula (I) as an active ingredient together with pharmaceutically  
15 acceptable carriers:



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, x and y have the same meanings as defined in claim 1.